Hemostatic abnormalities and liver diseases

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 8, 2008, Pages 772-778

  Wada, Hideo ^a   Usui, Masanobu ^a   Sakuragawa, Nobuo ^b,c  

^a MIE UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c Toyoura Hospital   (Japan)

Author keywords

Disseminated intravascular coagulation; Hemostasis; Liver disease; Vitamin K deficiency

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FATTY ACID BINDING PROTEIN; FIBRINOGEN; HIGH MOLECULAR WEIGHT KININOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREKALLIKREIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOMODULIN; THROMBOPOIETIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VITAMIN K GROUP; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; DISEASE MARKER; DISSEMINATED INTRAVASCULAR CLOTTING; ESOPHAGUS HEMORRHAGE; ESOPHAGUS VARICES; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER PARENCHYMA; LIVER SURGERY; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RETICULOENDOTHELIAL SYSTEM; REVIEW; SCLEROTHERAPY; THROMBOCYTE; VITAMIN K DEFICIENCY;

BLOOD COAGULATION DISORDERS; HEMOSTASIS; HUMANS; LIVER DISEASES;

EID: 60549083323     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1145259     Document Type: Review

References (48)

1. Mammen EF. Coagulopathies of liver disease. Clin Lab Med 1994;14:769-780
2. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994;78:545-554
3. Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992;6:1247-1257
4. Mammen EF. Blood coagulation disorders in liver diseases. Dtsch Med Wochenschr 1970;95:2241-2242
5. Carlier M, Van Obbergh LJ, Veyckemans F, et al. Hemostasis in children undergoing liver transplantation. Semin Thromb Hemost 1993;19:218-222
6. Matsumoto T, Wada H, Nishiyama H, et al. Hemostatic abnormalities and changes following bone marrow transplantation. Clin Appl Thromb Hemost 2004;10:341-350
7. Stafford DW. The vitamin K cycle. J Thromb Haemost 2005;3:1873-1878
8. Aljabiri MR, Lodato F, Burroughs AK. Surveillance and diagnosis for hepatocellular carcinoma. Liver Transpl 2007;13:S2-S12
9. Tripodi A, Chantarangkul V, Mannucci PM. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. J Thromb Haemost 2008;6:243-248
10. Akiyama K, Nakamura K, Makino I, et al. Antithrombin III producing hepatocellular carcinoma. Thromb Res 1993;72:193-201
11. Koike C, Hayakawa Y, Niiya K, Sakuragawa N, Sasaki H. The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1. Thromb Haemost 1996;75:298-302
12. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998;24:19-25
13. Mammen EF. Clinical relevance of antithrombin deficiencies. Semin Hematol 1995;32(Suppl 2):2-6
14. Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost 1998;24:293-297
15. Hirose K, Okajima K, Uchiba M, Nakano KY, Utoh J, Kitamura N. Antithrombin reduces the ischemia/reperfusion-induced spinal cord injury in rats by attenuating inflammatory responses. Thromb Haemost 2004;91:162-170
16. Warren BL, Eid A, Singer P, et al. KyberSept Trial Study Group: caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-1878
17. Kienast J, Juers M, Wiedermann CJ, et al. KyberSept investigators: treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90-97
18. Sakuragawa N. Regulation of thrombosis and hemostasis by antithrombin. Semin Thromb Hemost 1997;23:557-562
19. Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol 2004;76:225-229
20. Griffin GC, Mammen EF, Sokol RJ, Perrotta AL, Stoyanovich A, Abildgaard CF. Alpha 2-antiplasmin deficiency. An overlooked cause of hemorrhage. Am J Pediatr Hematol Oncol 1993;15:328-330
21. Koyama T, Kakishita E, Nakai Y, Okamoto E. Significance of hemostatic molecular markers during disseminated intravascular coagulation in patients with liver cirrhosis treated by endoscopic embolization for esophageal varices. Am J Hematol 1991;38:90-94
22. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-3469
23. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-1666
24. Faeh M, Hauser SP, Nydegger UE. Transient thrombopoietin peak after liver transplantation for end-stage liver disease. Br J Haematol 2001;112:493-498
25. Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 2002;75:25-34
26. Ko S, Okano E, Kanehiro H, et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl 2006;12:859-869
27. Taylor FB Jr, Toh CH, Hoots K, Wada H, Levi M. Towards a definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-1330
28. Wada H. Disseminated intravascular coagulation. Clin Chim Acta 2004;344:13-21
29. Soria J, Soria C, Ryckewaert JJ, Samama M, Thomson JM, Poller L. Study of acquired dysfibrinogenaemia in liver disease. Thromb Res 1980;19:29-41
30. Hoak DR, Mammen EF, Banerjee SK, Kaldor G. A fully automated immuno-turbidimetric determination of fibrin (ogen) degradation products. Thromb Res 1986;44:1-10
31. Wada H, Kobayashi T, Abe Y, et al. Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost 2006;4:1253-1258
32. de Moerloose P, Palareti G, Aguilar C, Legnani C, Reber G, Peetz D. A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. Thromb Haemost 2008;100:505-512
33. Roffi L, Colloredo G, Pioltelli P, et al. Gruppo Epatologico Lombardo. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008;13:663-673
34. Wilson RF, Mammen E, Walt AJ. Eight years of experience with massive blood transfusions. J Trauma 1971;11:275-285
35. Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol 2005;83:106-118
36. Gando S, Iba T, Eguchi Y, et al, for the Japanese Association for Acute Medicine Disseminated Intravascular Coagulation. (JAAM DIC) Study Group: a multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006;34:625-631
37. Dargaud Y, Desmurs-Clavel H, Marin S, Bordet JC, Poplavsky JL, Negrier C. Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study. J Thromb Haemost 2008;6:962-968
38. Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. Semin Thromb Hemost 2004;30:683-695
39. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-541
40. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2008; June 23 [Epub ahead of print]
41. Wilson RF, Mammen EF, Robson MC, Heggers JP, Soullier G, DePoli PA. Antithrombin, prekallikrein, and fibronectin levels in surgical patients. Arch Surg 1986;121:635-640
42. Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006;12:7725-7736
43. Bezeaud A, Denninger MH, Dondero F, et al. Hypercoagulability after partial liver resection. Thromb Haemost 2007;98:1252-1256
44. Porte RJ. Coagulation and fibrinolysis in orthotopic liver transplantation: current views and insights. Semin Thromb Hemost 1993;19:191-196
45. Abe Y, Wada H, Yamada E, et al. The effectiveness of measuring for fragmented red cells using an automated hematology analyzer in patients with thrombotic microangiopathy. Clin Appl Thromb Hemost 2008; July 3 [Epud ahead of print]
46. Cerutti E, Stratta C, Romagnoli R, et al. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl 2004;10:289-294
47. Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease. Blood Coagul Fibrinolysis 1995;6:S26-S31
48. Fujii Y, Sugawa C, Ozawa T, Nakumura R, Brown-Castillo J, Mammen EF. Hemostasis activation during esophageal variceal sclerotherapy with thrombin in cirrhotics. Am Surg 1991;57:222-225